Risk Prediction Equations for Atherosclerotic CVD Perform Similarly by Race
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 4, 2024 -- Risk prediction equations for atherosclerotic cardiovascular disease (ASCVD) perform similarly by race but are worse in men than women, according to a study published online Dec. 6 in JAMA Cardiology.
Arnab K. Ghosh, M.D., from Cornell University in New York City, and colleagues quantified the incremental value of race-specific pooled cohort risk equations (PCEs) and determined whether adding social determinants of health (SDOH) instead of race improves model performance. The analysis included 11,638 participants aged 45 to 79 years without ASCVD from the biracial Reasons for Geographic and Racial Differences in Stroke prospective cohort study. Participants were followed up to 10 years for incident ASCVD.
The researchers found that the C statistics did not change substantively across all strata compared with model C (a set of best-fit, race-stratified equations including the same variables as in the original PCE: Black female, 0.71; Black male, 0.68; White female, 0.77; and White male, 0.68), in model D (best-fit equations without race stratification: 0.71, 0.68, 0.76, and 0.68, respectively), or in model E (best-fit equations without race stratification but including SDOH as covariates: 0.72, 0.68, 0.77, and 0.68, respectively). For men but not for women, comparing model D with model E using the Net Reclassification Index showed a decrease in net percentage in the correct assignment to higher risk. In each model series, the Nam D'Agostino test was not significant for all race-sex strata, indicating good calibration in all groups.
"Our findings suggest reconsideration of the role of race stratification in the PCE as currently constructed," the authors write.
Several authors disclosed ties to the pharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Statins Reduce CVD Risk in Adults Aged 75 to 85 and 85 Years and Older
TUESDAY, May 28, 2024 -- For patients aged 75 years and older, statin therapy is associated with a risk reduction in cardiovascular diseases (CVDs), according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.